• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奥密克戎变异株流行期间医护人员混打疫苗策略的风险降低分析:台湾的一项多中心队列研究。

Risk reduction analysis of mix-and-match vaccination strategy in healthcare workers during SARS-CoV-2 Omicron variant predominant period: A multi-center cohort study in Taiwan.

机构信息

Division of Pediatric Infectious Diseases, Department of Pediatrics, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.

Molecular Infectious Disease Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.

出版信息

Hum Vaccin Immunother. 2023 Aug 1;19(2):2237387. doi: 10.1080/21645515.2023.2237387.

DOI:10.1080/21645515.2023.2237387
PMID:37534447
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10402828/
Abstract

This study investigated the relative effectiveness of a mix-and-match vaccination strategy, primarily comprising ChAdOx1 nCOV-19, mRNA-1273, BNT162b2, and a protein-based vaccine, MVC-COV1901, against COVID-19 in a healthcare worker (HCW) cohort in Taiwan during a period when the Omicron variant was predominant. The analysis included a total of 21,729 HCWs and recorded 3,672 infections with no severe disease nor death. Two main findings were observed from the study. Firstly, for those with ChAdOx1 nCOV-19 as primary series, a booster dose with BNT162b2 was associated with a small decrease in the risk of acquiring infection compared to those with mRNA-1273 as a booster (Adjust hazard ratio [Adj HR] 0.864; 95% confidence interval [CI] 0.761‒0.981,  = .024). Secondly, for HCWs receiving an mRNA-1273 booster, compared to those receiving ChAdOx1 nCOV-19 as the primary series, mixed primary series and homologous mRNA-1273 primary series were associated with a higher (Adj HR 1.144; 95% CI 1.021‒1.282,  = .021) and lower risk (Adj HR 0.735; 95% CI 0.671‒0.805,  < .001) of acquiring infection, respectively. Our study demonstrated that mix-and-match vaccination strategy may be associated with different level of risk reduction in acquiring infection, and sizable, prospective studies are encouraged to further elucidate our observation.

摘要

本研究调查了一种混合接种策略在台湾医疗保健工作者(HCW)队列中的相对有效性,该策略主要包括 ChAdOx1 nCOV-19、mRNA-1273、BNT162b2 和基于蛋白的疫苗 MVC-COV1901,针对的是在奥密克戎变体占主导地位期间的 COVID-19。该分析共纳入了 21729 名 HCW,并记录了 3672 例感染,无严重疾病或死亡。该研究观察到了两个主要发现。首先,对于以 ChAdOx1 nCOV-19 作为主要系列的人,与以 mRNA-1273 作为加强针相比,接种 BNT162b2 加强针与感染风险略有降低相关(调整后的危险比 [Adj HR] 0.864;95%置信区间 [CI] 0.761-0.981,  = .024)。其次,对于接受 mRNA-1273 加强针的 HCW,与接受 ChAdOx1 nCOV-19 作为主要系列的人相比,混合主要系列和同源 mRNA-1273 主要系列与更高(Adj HR 1.144;95%CI 1.021-1.282,  = .021)和更低(Adj HR 0.735;95%CI 0.671-0.805,  < .001)的感染风险相关。我们的研究表明,混合接种策略可能与感染风险降低的不同水平相关,鼓励进行更大规模的前瞻性研究来进一步阐明我们的观察结果。

相似文献

1
Risk reduction analysis of mix-and-match vaccination strategy in healthcare workers during SARS-CoV-2 Omicron variant predominant period: A multi-center cohort study in Taiwan.奥密克戎变异株流行期间医护人员混打疫苗策略的风险降低分析:台湾的一项多中心队列研究。
Hum Vaccin Immunother. 2023 Aug 1;19(2):2237387. doi: 10.1080/21645515.2023.2237387.
2
Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial.两剂腺病毒载体新冠疫苗(ChAdOx1 nCov-19)基础免疫后异源加强接种对医护人员体内针对 SARS-CoV-2 变异株中和抗体滴度和广度的影响:一项单盲、随机临床试验。
J Clin Virol. 2022 Dec;157:105328. doi: 10.1016/j.jcv.2022.105328. Epub 2022 Nov 12.
3
Waning of humoral immunity depending on the types of COVID-19 vaccine.体液免疫的减弱取决于新冠疫苗的类型。
Infect Dis (Lond). 2023 Mar;55(3):216-220. doi: 10.1080/23744235.2023.2165707. Epub 2023 Jan 10.
4
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.ChAdOx1 nCoV-19 和 BNT162b2 同源和异源加强免疫的安全性、反应原性和免疫原性:一项前瞻性队列研究。
Lancet Respir Med. 2021 Nov;9(11):1255-1265. doi: 10.1016/S2213-2600(21)00357-X. Epub 2021 Aug 13.
5
Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan.基于人群的 SARS-CoV-2 感染、重症和死亡疫苗有效性评估,中国台湾。
Emerg Infect Dis. 2024 Mar;30(3):478-489. doi: 10.3201/eid3003.230893. Epub 2024 Jan 31.
6
Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study.mRNA 疫苗加强针在西班牙针对 SARS-CoV-2 奥密克戎(B.1.1.529)变异株感染的有效性:一项全国性队列研究。
Lancet Infect Dis. 2022 Sep;22(9):1313-1320. doi: 10.1016/S1473-3099(22)00292-4. Epub 2022 Jun 2.
7
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.COVID-19 疫苗效力下降和加强针的有效性和副作用:来自 ZOE COVID 研究的一项前瞻性社区研究。
Lancet Infect Dis. 2022 Jul;22(7):1002-1010. doi: 10.1016/S1473-3099(22)00146-3. Epub 2022 Apr 8.
8
[COVID-19 infections and effectiveness of the vaccination among healthcare workers].[医护人员中的新冠病毒感染情况及疫苗接种效果]
Orv Hetil. 2023 Feb 5;164(5):163-171. doi: 10.1556/650.2023.32709.
9
Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data.mRNA-BNT162b2、mRNA-1273 和 ChAdOx1 nCoV-19 疫苗在医护人员中预防 COVID-19 的有效性:基于监测数据的观察性研究。
Clin Microbiol Infect. 2021 Nov;27(11):1699.e5-1699.e8. doi: 10.1016/j.cmi.2021.06.043. Epub 2021 Jul 13.
10
Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.在使用 ChAdOx1 nCOV-19 疫苗进行初级免疫后,BNT162b2 或 mRNA-1273 第二针后医护人员的不良反应率。
Clin Microbiol Infect. 2022 Jun;28(6):885.e1-885.e5. doi: 10.1016/j.cmi.2022.02.010. Epub 2022 Feb 16.

引用本文的文献

1
The XEC Variant: Genomic Evolution, Immune Evasion, and Public Health Implications.XEC变体:基因组进化、免疫逃逸及对公共卫生的影响
Viruses. 2025 Jul 15;17(7):985. doi: 10.3390/v17070985.
2
Co-detection of various viruses in SARS-CoV-2 in children with respiratory infections.呼吸道感染儿童中新冠病毒与多种病毒的联合检测
Sci Rep. 2025 Mar 10;15(1):8312. doi: 10.1038/s41598-025-92878-w.
3
Acute and post-acute respiratory complications of SARS-CoV-2 infection: population-based cohort study in South Korea and Japan.SARS-CoV-2 感染的急性和后期呼吸道并发症:韩国和日本基于人群的队列研究。
Nat Commun. 2024 May 27;15(1):4499. doi: 10.1038/s41467-024-48825-w.
4
Epidemiology and analysis of SARS-CoV-2 Omicron subvariants BA.1 and 2 in Taiwan.台湾地区 SARS-CoV-2 奥密克戎变异株 BA.1 和 2 的流行病学和分析。
Sci Rep. 2023 Oct 3;13(1):16583. doi: 10.1038/s41598-023-43357-7.

本文引用的文献

1
Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial.两剂腺病毒载体新冠疫苗(ChAdOx1 nCov-19)基础免疫后异源加强接种对医护人员体内针对 SARS-CoV-2 变异株中和抗体滴度和广度的影响:一项单盲、随机临床试验。
J Clin Virol. 2022 Dec;157:105328. doi: 10.1016/j.jcv.2022.105328. Epub 2022 Nov 12.
2
A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19.一种异源 ChAdOx1 nCoV-19 和重组亚单位疫苗 MVC-COV1901 对 COVID-19 的随机对照试验。
Nat Commun. 2022 Sep 17;13(1):5466. doi: 10.1038/s41467-022-33146-7.
3
Acute myocarditis following a third dose of COVID-19 mRNA vaccination in adults.成年人接种第三剂 COVID-19 mRNA 疫苗后出现急性心肌炎。
Int J Cardiol. 2022 Oct 15;365:41-43. doi: 10.1016/j.ijcard.2022.07.031. Epub 2022 Jul 21.
4
Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.全球首例 COVID-19 疫苗接种一年的影响:一项数学建模研究。
Lancet Infect Dis. 2022 Sep;22(9):1293-1302. doi: 10.1016/S1473-3099(22)00320-6. Epub 2022 Jun 23.
5
Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study.南非卫生保健工作者中 Ad26.COV2.S 疫苗的有效性(Sisonke 研究):一项单臂、开放标签、3B 期、实施研究的结果。
Lancet. 2022 Mar 19;399(10330):1141-1153. doi: 10.1016/S0140-6736(22)00007-1.
6
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.Covid-19 疫苗对奥密克戎(B.1.1.529)变异株的有效性。
N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2.
7
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.在英国,用 ChAdOx1 nCov-19 或 BNT162b2 接种两剂后作为第三剂(加强针)接种 7 种 COVID-19 疫苗的安全性和免疫原性(COV-BOOST):一项盲法、多中心、随机、对照、2 期试验。
Lancet. 2021 Dec 18;398(10318):2258-2276. doi: 10.1016/S0140-6736(21)02717-3. Epub 2021 Dec 2.
8
Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.CpG 1018 和氢氧化铝佐剂的 SARS-CoV-2 S-2P 蛋白疫苗 MVC-COV1901 的安全性和免疫原性:台湾一项大规模、双盲、随机、安慰剂对照 2 期临床试验的中期结果。
Lancet Respir Med. 2021 Dec;9(12):1396-1406. doi: 10.1016/S2213-2600(21)00402-1. Epub 2021 Oct 13.
9
Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel.mRNA 新冠病毒疫苗在美国医护人员中的有效性。
N Engl J Med. 2021 Dec 16;385(25):e90. doi: 10.1056/NEJMoa2106599. Epub 2021 Sep 22.
10
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination.异源ChAdOx1 nCoV-19疫苗和mRNA-1273疫苗接种
N Engl J Med. 2021 Sep 9;385(11):1049-1051. doi: 10.1056/NEJMc2110716. Epub 2021 Jul 14.